9.1 Principles of Pharmacology, Drug Classifications, and Controlled Substances

9.1 Principles of Pharmacology, Drug Classifications, and Controlled Substances

Pharmacology is the science of drugs, including their origin, composition, pharmacokinetics, therapeutic uses, and toxicology. For the Certified Medical Assistant (NCMA), mastering pharmacological principles is paramount for ensuring patient safety, preventing adverse drug reactions, and administering medications accurately.

Core Concepts: Pharmacodynamics vs. Pharmacokinetics

To understand how drugs work, medical assistants must distinguish between two fundamental disciplines:

• Pharmacodynamics: What the drug does to the body. This involves receptor binding, post-receptor effects, chemical interactions, and physiological responses (e.g., lowering blood pressure, reducing inflammation, or inhibiting bacterial cell wall synthesis).
• Pharmacokinetics: What the body does to the drug. This describes the quantitative movement of a drug through the body over time across four sequential phases: Absorption, Distribution, Metabolism, and Excretion (commonly remembered by the acronym ADME).

---

The Pharmacokinetic Cycle (ADME)

1. Absorption

Absorption is the process by which a drug moves from its site of administration into the bloodstream. The rate and extent of absorption depend on the route of administration, drug solubility, pH of the environment, and blood flow to the administration site.

• Bioavailability: The percentage of an administered drug dose that reaches the systemic circulation in an active form. Intravenous (IV) administration yields 100% bioavailability because the drug is delivered directly into the vascular system. Oral medications have lower bioavailability due to incomplete absorption and hepatic metabolism.

2. Distribution

Distribution is the movement of the absorbed drug through the bloodstream to body tissues, organs, and target sites.

• Protein Binding: Many drugs bind reversibly to plasma proteins, primarily albumin. Only the unbound ("free") drug molecules can cross cell membranes, interact with target receptors, and exert therapeutic effects. Patients with hypoalbuminemia (e.g., liver disease, malnutrition) have higher levels of free drug, increasing the risk of toxicity.
• Anatomical Barriers: Specialized tissue structures limit distribution. The blood-brain barrier (BBB) restricts central nervous system penetration to highly lipid-soluble drugs, protecting the brain from toxins. The placental barrier allows many drugs to cross into fetal circulation, requiring cautious prescribing during pregnancy.

3. Metabolism (Biotransformation)

Metabolism is the chemical alteration of a drug by body enzymes, converting lipid-soluble compounds into water-soluble metabolites for easier elimination. The primary site of drug metabolism is the liver, utilizing the cytochrome P450 (CYP450) enzyme system.

• First-Pass Effect (Hepatic First-Pass Metabolism): When drugs are swallowed, they are absorbed across the gastrointestinal mucosa into the portal venous circulation and transported directly to the liver before reaching systemic circulation. Hepatic enzymes may extensively metabolize the drug, significantly reducing its bioavailability. Nitroglycerin, for example, undergoes near 100% first-pass destruction if swallowed, which is why it is administered sublingually to bypass the liver.

4. Excretion

Excretion is the permanent removal of drug molecules and metabolites from the body. The kidneys are the primary organs of drug excretion through renal filtration, tubular secretion, and reabsorption.

• Secondary Excretion Routes: Include the gastrointestinal tract (biliary/fecal elimination), lungs (exhalation of volatile anesthetics and alcohol), skin (sweat), and mammary glands (breast milk).
• Half-Life ($t_{1/2}$): The time required for the blood concentration of a drug to decrease by 50%. Half-life determines dosing frequency. It generally takes 4 to 5 half-lives for a drug to be eliminated from the body, or to reach a stable therapeutic level ("steady state").

---

Controlled Substances Act (CSA) and Scheduling

The Controlled Substances Act (CSA) of 1970 is the legal framework regulating manufacturing, importation, possession, distribution, and dispensing of chemicals with abuse potential. The law is enforced by the Drug Enforcement Administration (DEA). Controlled substances are categorized into five schedules based on their accepted medical use, abuse potential, and risk of physical or psychological dependence.

Clinical and Administrative Safeguards for Controlled Substances

• DEA Registration: Any provider prescribing controlled substances must possess a valid DEA registration number.
• Storage & Security: Schedule II–V drugs must be stored in a double-locked cabinet or secure automated dispensing machine (e.g., Pyxis). Access is strictly restricted to authorized licensed personnel.
• Inventory & Counts: A physical inventory count must be performed at the beginning and end of every shift by two licensed staff members. Discrepancies must be reported immediately to the clinic manager and DEA.

Major Therapeutic Drug Classifications

Medical Assistants must be familiar with common therapeutic drug categories, their mechanisms, characteristic naming stems (prefixes/suffixes), and critical clinical monitoring parameters.

1. Antihypertensives

Used to treat hypertension and reduce cardiovascular mortality.

• ACE Inhibitors (Stem: -pril; e.g., Lisinopril, Enalapril): Inhibit angiotensin-converting enzyme. Key side effects include dry cough and hyperkalemia.
• Angiotensin II Receptor Blockers (ARBs) (Stem: -sartan; e.g., Losartan, Valsartan): Block angiotensin II receptors. Used when patients cannot tolerate ACE inhibitor cough.
• Beta-Blockers (Stem: -olol; e.g., Metoprolol, Atenolol): Block beta-adrenergic receptors, reducing heart rate and cardiac output. Monitor for bradycardia and bronchospasm (avoid non-selective beta-blockers in asthma).
• Calcium Channel Blockers (CCBs) (Stem: -dipine; e.g., Amlodipine, Nifedipine): Inhibit calcium entry into vascular smooth muscle, causing vasodilation. Side effect: peripheral edema.
• Diuretics: Promote excretion of sodium and water by kidneys (e.g., Hydrochlorothiazide, Furosemide). Monitor potassium levels.

2. Antibiotics

Used to treat bacterial infections. Patient education emphasizes completing the full course to prevent resistance.

• Penicillins (Stem: -cillin; e.g., Amoxicillin, Penicillin V): Inhibit bacterial cell wall synthesis. High risk of allergic reactions (cross-sensitivity with cephalosporins).
• Cephalosporins (Prefix: cef- or ceph-; e.g., Cephalexin, Ceftriaxone): Cell wall synthesis inhibitors structured similarly to penicillins.
• Macrolides (Stem: -thromycin; e.g., Azithromycin, Erythromycin): Protein synthesis inhibitors. Common alternative for penicillin-allergic patients.
• Fluoroquinolones (Stem: -floxacin; e.g., Ciprofloxacin, Levofloxacin): DNA synthesis inhibitors. Black Box Warning for tendonitis and tendon rupture.
• Tetracyclines (Stem: -cycline; e.g., Doxycycline): Protein synthesis inhibitors. Contraindicated in pregnancy and children under 8 due to tooth discoloration; causes photosensitivity.

3. Anticoagulants and Antiplatelets

Prevent blood clot formation in deep vein thrombosis, pulmonary embolism, and atrial fibrillation.

• Warfarin (Coumadin): Oral vitamin K antagonist. Requires regular PT/INR blood monitoring. Antidote: Vitamin K.
• Heparin: Parenteral anticoagulant. Requires aPTT monitoring. Antidote: Protamine Sulfate.
• DOACs (Direct Oral Anticoagulants; e.g., Apixaban, Rivaroxaban): Factor Xa inhibitors requiring less routine blood monitoring.
• Antiplatelets (e.g., Aspirin, Clopidogrel/Plavix): Prevent blood platelet aggregation.

4. Antidiabetics

Manage blood glucose levels in diabetes mellitus.

• Insulin: Parenteral protein hormone. Formulations range from Rapid-Acting (Lispro/Humalog), Short-Acting (Regular), Intermediate-Acting (NPH), to Long-Acting (Glargine/Lantus). High-alert medication.
• Biguanides (Metformin): First-line oral drug for Type 2 diabetes. Decreases hepatic glucose production. Must be withheld 48 hours before and after IV iodinated contrast dye to prevent lactic acidosis.
• Sulfonylureas (e.g., Glipizide, Glyburide): Stimulate pancreatic beta cells to release insulin. Main risk: hypoglycemia.

5. Bronchodilators & Respiratory Agents

Relieve bronchospasm in asthma and COPD.

• Short-Acting Beta-2 Agonists (SABA) (e.g., Albuterol): Rescue bronchodilators for acute asthma attacks. Side effects: tachycardia and tremors.
• Inhaled Corticosteroids (ICS) (e.g., Fluticasone, Budesonide): Maintenance anti-inflammatory drugs. Patients must rinse mouth after use to prevent oral candidiasis (thrush).

6. Analgesics

Relieve pain without loss of consciousness.

• NSAIDs (Nonsteroidal Anti-inflammatory Drugs; e.g., Ibuprofen, Naproxen): Inhibit COX enzymes to reduce pain, fever, and inflammation. Risks: GI bleeding and renal toxicity.
• Acetaminophen (Tylenol): Analgesic and antipyretic lacking anti-inflammatory activity. Hepatotoxic in high doses (maximum adult daily dose: 3,000 to 4,000 mg).
• Opioids (e.g., Morphine, Oxycodone, Fentanyl): Bind central opioid receptors. Major risk: respiratory depression. Antidote: Naloxone (Narcan).

7. Statins (Antihyperlipidemics)

• HMG-CoA Reductase Inhibitors (Stem: -statin; e.g., Atorvastatin, Simvastatin): Lower LDL cholesterol and cardiovascular risk. Patients should report unexplained muscle pain or weakness (sign of rhabdomyolysis). Liver enzymes should be monitored periodically.

---

Consulting Pharmaceutical Desk References

Before preparing or administering an unfamiliar medication, medical assistants must verify identity, dose, route, contraindications, and warnings in an authoritative drug reference. Guessing from memory is a medication-error risk and is not acceptable clinical practice.

Common Reference Sources

When the MA Must Consult a Reference

1. First-time administration of a medication unfamiliar to the assistant.
2. Any discrepancy among the order, label, and expected dose/route/form.
3. Look-alike / sound-alike drug names or unclear abbreviations.
4. Controlled-substance preparation requiring verification of strength and schedule.
5. Pediatric or weight-based dosing that must be cross-checked against labeled concentration.

Document the drug, dose, route, time, lot/expiration when required by policy, and patient response. If the reference information conflicts with the written order, do not administer—clarify with the ordering provider or pharmacist before proceeding.